Don't lose sight of what is at stake for all Enzo shareholders. Enzo is currently trading at ~1.0x sales compared to peer labs that trade at ~2.0x sales and peer life sciences companies that trade at a median of ~4.0x sales, with some of the better performing, faster growing peers exceeding 10.0x sales. We believe Enzo's discount to these peers is a direct result of Dr. Rabbani's disdain for shareholders and refusal to accept the reality that he only owns 3.8% of the Company.